Evaluation of reconstituted high-density lipoprotein (rHDL) as a drug delivery platform - a detailed survey of rHDL particles ranging from biophysical properties to clinical implications

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 12, Issue 7, 2016, Pages 2161-2179

  Simonsen, Jens B ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Magic bullet; Nanodiscs; Nanodisks; Reconstituted high density lipoproteins; RHDL; Targeted drug delivery

Indexed keywords

MEDICAL NANOTECHNOLOGY; NANOSTRUCTURED MATERIALS; NANOTECHNOLOGY;

HIGH DENSITY LIPOPROTEIN; MAGIC BULLETS; NANODISCS; NANODISKS; RHDL; TARGETED DRUG DELIVERY;

LIPOPROTEINS;

AMPHOTERICIN B; ANTINEOPLASTIC AGENT; APOLIPOPROTEIN A1; APOLIPOPROTEIN E; CURCUMIN; DISCOIDAL RECONSTITUTED HIGH DENSITY LIPOPROTEIN; DRUG CARRIER; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN RECEPTOR; LIPID; MEMBRANE PROTEIN; RETINOIC ACID; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; CARRIER PROTEIN;

BIOPHYSICS; CIRCULATION TIME; DRUG DISTRIBUTION; HUMAN; HYDROPHILICITY; IN VITRO STUDY; IN VIVO STUDY; INFUSION; LIPID ANALYSIS; LIPID COMPOSITION; LIPOPHILICITY; LIVER; NEOPLASM; NONHUMAN; PHARMACOKINETICS; PROTEIN ANALYSIS; PROTEIN STABILITY; REVIEW; SAFETY; CHEMICAL PHENOMENA; DRUG DELIVERY SYSTEM;

CARRIER PROTEINS; DRUG DELIVERY SYSTEMS; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; LIPOPROTEINS, HDL;

EID: 84977142649     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2016.05.009     Document Type: Review

References (136)

1. Jonas A, Phillips MC Lipoprotein structure. Biochemistry of Lipids. Lipoproteins and Membranes 2008, 485-506. Elsevier, Amsterdam. 5th ed. D.E. Vance, J.E. Vance (Eds.).
2. Kingwell B.A., Chapman M.J. Future of high-density lipoprotein infusion therapies: potential for clinical management of vascular disease. Circulation 2013, 128(10):1112-1121.
3. Kingwell B.A., Chapman M.J., Kontush A., Miller N.E. HDL-targeted therapies: progress, failures and future. Nat Rev Drug Discov 2014, 13(6):445-464.
4. Toth P.P., Barter P.J., Rosenson R.S., Boden W.E., Chapman M.J., Cuchel M., et al. High-density lipoproteins: a consensus statement from the National Lipid Association. J Clin Lipidol 2013, 7(5):484-525.
5. Vickers K.C., Remaley A.T. Thematic review series: high density lipoprotein structure, function, and metabolism HDL and cholesterol: life after the divorce?. J Lipid Res 2014, 55(1):4-12.
6. Rensen P.C.N., de Vrueh R.L.A., Kuiper J., Bijsterbosch M.K., Biessen E.A.L., van Berkel T.J.C. Recombinant lipoproteins: lipoprotein-like lipid particles for drug targeting. Adv Drug Deliv Rev 2001, 47(2-3):251-276.
7. Lacko A.G., Sabnis N.A., Nagarajan B., McConathy W.J. HDL as a drug and nucleic acid delivery vehicle. Front Pharmacol 2015, 6.
8. Damiano M.G., Mutharasan R.K., Tripathy S., McMahon K.M., Thaxton C.S. Templated high density lipoprotein nanoparticles as potential therapies and for molecular delivery. Adv Drug Deliv Rev 2013, 65(5):649-662.
9. Shih A.Y., Freddolino P.L., Sligar S.G., Schulten K. Disassembly of nanodiscs with cholate. Nano Lett 2007, 7(6):1692-1696.
10. Carney C.E., Lenov I.L., Baker C.J., MacRenaris K.W., Eckermann A.L., Sligar S.G., et al. Nanodiscs as a modular platform for multimodal MR-optical imaging. Bioconjug Chem 2015, 26(5):899-905.
11. Nakayama T., Butler J.S., Sehgal A., Severgnini M., Racie T., Sharman J., et al. Harnessing a physiologic mechanism for siRNA delivery with mimetic lipoprotein particles. Mol Ther 2012, 20(8):1582-1589.
12. Kynde S.A.R., Skar-Gislinge N., Pedersen M.C., Midtgaard S.R., Simonsen J.B., Schweins R., et al. Small-angle scattering gives direct structural information about a membrane protein inside a lipid environment. Acta Crystallogr D Biol Crystallogr 2014, 70:371-383.
13. Crosby N.M., Ghosh M., Su B., Beckstead J.A., Kamei A., Simonsen J.B., et al. Anti-CD20 single chain variable antibody fragment-apolipoprotein A-I chimera containing nanodisks promote targeted bioactive agent delivery to CD20-positive lymphomas. Biochem Cell Biol 2015, 93(4):343-350.
14. Borch J., Hamann T. The nanodisc: a novel tool for membrane protein studies. Biol Chem 2009, 390(8):805-814.
15. Skajaa T., Cormode D.P., Falk E., Mulder W.J., Fisher E.A., Fayad Z.A. High-density lipoprotein-based contrast agents for multimodal imaging of atherosclerosis. Arterioscler Thromb Vasc Biol 2010, 30(2):169-176.
16. Huda P., Binderup T., Pedersen M.C., Midtgaard S.R., Elema D.R., Kjaer A., et al. PET/CT based in vivo evaluation of Cu-64 labelled nanodiscs in tumor bearing mice. Plos One 2015, 10(7).
17. Kontush A., Therond P., Zerrad A., Couturier M., Negre-Salvayre A., de Souza J.A., et al. Preferential sphingosine-1-phosphate enrichment and sphingomyelin depletion are key features of small dense HDL3 particles - relevance to antiapoptotic and antioxidative activities. Arterioscler Thromb Vasc Biol 2007, 27(8):1843-1849.
18. Patel S., Drew B.G., Nakhla S., Duffy S.J., Murphy A.J., Barter P.J., et al. Reconstituted high-density lipoprotein increases plasma high-density lipoprotein anti-inflammatory properties and cholesterol efflux capacity in patients with type 2 diabetes. J Am Coll Cardiol 2009, 53(11):962-971.
19. de Souza J.A., Vindis C., Negre-Salvayre A., Rye K.A., Couturier M., Therond P., et al. Small, dense HDL 3 particles attenuate apoptosis in endothelial cells: pivotal role of apolipoprotein A-I. J Cell Mol Med 2010, 14(3):608-620.
20. Nofer J.R., Brodde M.F., Kehrel B.E. High-density lipoproteins, platelets and the pathogenesis of atherosclerosis. Clin Exp Pharmacol Physiol 2010, 37(7):726-735.
21. Calkin A.C., Drew B.G., Ono A., Duffy S.J., Gordon M.V., Schoenwaelder S.M., et al. Reconstituted high-density lipoprotein attenuates platelet function in individuals with type 2 diabetes mellitus by promoting cholesterol efflux. Circulation 2009, 120(21):2095-2104.
22. Feingold K.R., Grunfeld C. The role of HDL in innate immunity. J Lipid Res 2011, 52(1):1-3.
23. von Eckardstein A., Widmann C. High-density lipoprotein, beta cells, and diabetes. Cardiovasc Res 2014, 103(3):384-394.
24. Drew B.G., Rye K.A., Duffy S.J., Barter P., Kingwell B.A. The emerging role of HDL in glucose metabolism. Nat Rev Endocrinol 2012, 8(4):237-245.
25. Shah A.S., Tan L., Long J.L., Davidson W.S. Thematic review series: high density lipoprotein structure, function, and metabolism proteomic diversity of high density lipoproteins: our emerging understanding of its importance in lipid transport and beyond. J Lipid Res 2013, 54(10):2575-2585.
26. Kontush A., Lhomme M., Chapman M.J. Thematic review series: high density lipoprotein structure, function, and metabolism unraveling the complexities of the HDL lipidome. J Lipid Res 2013, 54(11):2950-2963.
27. Traber M.G., Diamond S.R., Lane J.C., Brody R.I., Kayden H.J. Beta-carotene transport in human lipoproteins - comparisons with alpha-tocopherol. Lipids 1994, 29(10):665-669.
28. Alwaili K., Bailey D., Awan Z., Bailey S.D., Ruel I., Hafiane A., et al. The HDL proteome in acute coronary syndromes shifts to an inflammatory profile. Biochim Biophys Acta 2012, 1821(3):405-415.
29. Balazs Z., Panzenboeck U., Hammer A., Sovic A., Quehenberger O., Malle E., et al. Uptake and transport of high-density lipoprotein (HDL) and HDL-associated alpha-tocopherol by an in vitro blood-brain barrier model. J Neurochem 2004, 89(4):939-950.
30. Vaisar T., Pennathur S., Green P.S., Gharib S.A., Hoofnagle A.N., Cheung M.C., et al. Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J Clin Investig 2007, 117(3):746-756.
31. Tikkanen M.J., Vihma V., Jauhiainen M., Hockerstedt A., Helisten H., Kaamanen M. Lipoprotein-associated estrogens. Cardiovasc Res 2002, 56(2):184-188.
32. Benvenga S., Cahnmann H.J., Gregg R.E., Robbins J. Characterization of the binding of thyroxine to high-density lipoproteins and Apolipoproteins A-I. J Clin Endocrinol Metab 1989, 68(6):1067-1072.
33. Regazzi R., Widmann C. Genetics and molecular biology: miRNAs take the HDL ride. Curr Opin Lipidol 2012, 23(2):165-166.
34. Vickers K.C., Palmisano B.T., Shoucri B.M., Shamburek R.D., Remaley A.T. MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell Biol 2011, 13(4):423-433.
35. Annema W., von Eckardstein A. High-density lipoproteins - multifunctional but vulnerable protections from atherosclerosis. Circ J 2013, 77(10):2432-2448.
36. Nissen S.E., Tsunoda T., Tuzcu E.M., Schoenhagen P., Cooper C.J., Yasin M., et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 2003, 290(17):2292-2300.
37. Tardif J.C., Gregoire J., L'Allier P.L., Ibrahim R., Lesperance J., Heinonen T.M., et al. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. JAMA 2007, 297(15):1675-1682.
38. Easton R., Gille A., D'Andrea D., Davis R., Wright S.D., Shear C. A multiple ascending dose study of CSL112, an infused formulation of ApoA-I. J Clin Pharmacol 2014, 54(3):301-310.
39. Gille A., Easton R., D'Andrea D., Wright S.D., Shear C.L. CSL112 enhances biomarkers of reverse cholesterol transport after single and multiple infusions in healthy subjects. Arterioscler Thromb Vasc Biol 2014, 34(9):2106-2114.
40. Gille A., Easton R., Wright S., Shear C. CSL112, a novel formulation of human apolipoprotein A-I, dramatically increases cholesterol efflux capacity in healthy subjects: a, placebo-controlled, double-blinded, randomized single ascending dose study. Circulation 2012, 126(21).
41. Gille A., D'Andrea D., Easton R., Tricoci P., Alexander J.H., Wright S.D., et al. CSL112, a novel formulation of human apolipoprotein A-I, dramatically increases cholesterol efflux capacity in patients with stable atherothrombotic disease: a multicenter, randomized, double-blind, placebo-controlled, ascending-dose study. Circulation 2013, 128(22).
42. Tardif J.C., Ballantyne C.M., Barter P., Dasseux J.L., Fayad Z.A., Guertin M.C., et al. Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial. Eur Heart J 2014, 35(46):3277-3286.
43. Keyserling C.H., Hunt T.L., Klepp H.M., Scott R.A., Barbaras R., Schwendeman A., et al. CER-001, a synthetic HDL-mimetic, safely mobilizes cholesterol in healthy dyslipidemic volunteers. Circulation 2011, 124(21).
44. Aseem O., Smith B.T., Cooley M.A., Wilkerson B.A., Argraves K.M., Remaley A.T., et al. Cubilin maintains blood levels of HDL and albumin. J Am Soc Nephrol 2014, 25(5):1028-1036.
45. Acton S., Rigotti A., Landschulz K.T., Xu S.Z., Hobbs H.H., Krieger M. Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. Science 1996, 271(5248):518-520.
46. Voisset C., Callens N., Blanchard E., Dubuisson J., Vu-Dac N. High density lipoproteins facilitate hepatitis C virus entry through the scavenger receptor class B type I. J Biol Chem 2005, 280(9):7793-7799.
47. Vishnyakova T.G., Bocharov A.V., Baranova I.N., Chen Z.G., Remaley A.T., Csako G., et al. Binding and internalization of lipopolysaccharide by Cla-1, a human orthologue of rodent scavenger receptor B1. J Biol Chem 2003, 278(25):22771-22780.
48. Silver D.L., Wang N., Xiao X., Tall A.R. High density lipoprotein (HDL) particle uptake mediated by scavenger receptor class B type 1 results in selective sorting of HDL cholesterol from protein and polarized cholesterol secretion. J Biol Chem 2001, 276(27):25287-25293.
49. Neculai D., Schwake M., Ravichandran M., Zunke F., Collins R.F., Peters J., et al. Structure of LIMP-2 provides functional insights with implications for SR-BI and CD36. Nature 2013, 504(7478):172-176.
50. Cao G.P., Garcia C.K., Wyne K.L., Schultz R.A., Parker K.L., Hobbs H.H. Structure and localization of the human gene encoding SR-BI/CLA-1 - evidence for transcriptional control by steroidogenic factor 1. J Biol Chem 1997, 272(52):33068-33076.
51. Krieger M. Charting the fate of the "good cholesterol": Identification and characterization of the high-density lipoprotein receptor SR-BI. Annu Rev Biochem 1999, 68:523-558.
52. Martinez L.O., Jacquet S., Esteve J.P., Rolland C., Cabezon E., Champagne E., et al. Ectopic beta-chain of ATP synthase is an apolipoprotein A-I receptor in hepatic HDL endocytosis. Nature 2003, 421(6918):75-79.
53. Goldstein J.L., Brown M.S., Anderson R.G.W., Russell D.W., Schneider W.J. Receptor-mediated endocytosis - concepts emerging from the Ldl receptor system. Annu Rev Cell Biol 1985, 1:1-39.
54. Bilheimer D.W., Goldstein J.L., Grundy S.M., Starzl T.E., Brown M.S. Liver-transplantation to provide low-density-lipoprotein receptors and lower plasma-cholesterol in a child with homozygous familial hypercholesterolemia. N Engl J Med 1984, 311(26):1658-1664.
55. Leon C.G., Locke J.A., Adomat H.H., Etinger S.L., Twiddy A.L., Neumann R.D., et al. Alterations in cholesterol regulation contribute to the production of intratumoral androgens during progression to castration-resistant prostate cancer in a mouse xenograft model. Prostate 2010, 70(4):390-400.
56. Cao W.M., Murao K., Imachi H., Yu X., Abe H., Yamauchi A., et al. A mutant high-density lipoprotein receptor inhibits proliferation of human breast cancer cells. Cancer Res 2004, 64(4):1515-1521.
57. Lobo M.V., Huerta L., Ruiz-Velasco N., Teixeiro E., de la Cueva P., Celdran A., et al. Localization of the lipid receptors CD36 and CLA-1/SR-BI in the human gastrointestinal tract: towards the identification of receptors mediating the intestinal absorption of dietary lipids. J Histochem Cytochem 2001, 49(10):1253-1260.
58. Su F., Kozak K.R., Imaizumi S., Gao F., Amneus M.W., Grijalva V., et al. Apolipoprotein A-I (apoA-I) and apoA-I mimetic peptides inhibit tumor development in a mouse model of ovarian cancer. Proc Natl Acad Sci U S A 2010, 107(46):19997-20002.
59. Zheng Y., Liu Y.Y., Jin H.L., Pan S.T., Qian Y., Huang C., et al. Scavenger receptor B1 is a potential biomarker of human nasopharyngeal carcinoma and its growth is inhibited by HDL-mimetic nanoparticles. Theranostics 2013, 3(7):477-486.
60. Vitols S. Uptake of low-density lipoprotein by malignant cells--possible therapeutic applications. Cancer Cells 1991, 3(12):488-495.
61. Siperstein M.D. Role of cholesterogenesis and isoprenoid synthesis in DNA-replication and cell-growth. J Lipid Res 1984, 25(13):1462-1468.
62. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144(5):646-674.
63. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100(1):57-70.
64. Pugliese L., Bernardini I., Pacifico N., Peverini M., Damaskopoulou E., Cataldi S., et al. Severe hypocholesterolaemia is often neglected in haematological malignancies. Eur J Cancer 2010, 46(9):1735-1743.
65. Pluen A., Boucher Y., Ramanujan S., McKee T.D., Gohongi T., di Tomaso E., et al. Role of tumor-host interactions in interstitial diffusion of macromolecules: cranial vs. subcutaneous tumors. Proc Natl Acad Sci U S A 2001, 98(8):4628-4633.
66. Schouten D., Vanderkooij M., Muller J., Pieters M.N., Bijsterbosch M.K., Vanberkel T.J.C. Development of lipoprotein-like lipid particles for drug targeting - neo-high density lipoproteins. Mol Pharmacol 1993, 44(2):486-492.
67. Corbin I.R., Ng K.K., Ding L., Jurisicova A., Zheng G. Near-infrared fluorescent imaging of metastatic ovarian cancer using folate receptor-targeted high-density lipoprotein nanocarriers. Nanomedicine 2013, 8(6):875-890.
68. Kalli K.R., Oberg A.L., Keeney G.L., Christianson T.J., Low P.S., Knutson K.L., et al. Folate receptor alpha as a tumor target in epithelial ovarian cancer. Gynecol Oncol 2008, 108(3):619-626.
69. Mooberry L.K., Nair M., Paranjape S., McConathy W.J., Lacko A.G. Receptor mediated uptake of paclitaxel from a synthetic high density lipoprotein nanocarrier. J Drug Target 2010, 18(1):53-58.
70. Iovannisci D.M., Beckstead J.A., Ryan R.O. Targeting nanodisks via a single chain variable antibody--apolipoprotein chimera. Biochem Biophys Res Commun 2009, 379(2):466-469.
71. Murakami T., Wijagkanalan W., Hashida M., Tsuchida K. Intracellular drug delivery by genetically engineered high-density lipoprotein nanoparticles. Nanomedicine 2010, 5(6):867-879.
72. Burgess B.L., He Y., Baker M.M., Luo B., Carroll S.F., Forte T.M., et al. NanoDisk containing super aggregated amphotericin B: a high therapeutic index antifungal formulation with enhanced potency. Int J Nanomedicine 2013, 8:4733-4743.
73. Oda M.N., Hargreaves P.L., Beckstead J.A., Redmond K.A., van Antwerpen R., Ryan R.O. Reconstituted high density lipoprotein enriched with the polyene antibiotic amphotericin B. J Lipid Res 2006, 47(2):260-267.
74. Nelson K.G., Bishop J.V., Ryan R.O., Titus R. Nanodisk-associated amphotericin B clears Leishmania major cutaneous infection in susceptible BALB/c mice. Antimicrob Agents Chemother 2006, 50(4):1238-1244.
75. Altucci L., Gronemeyer H. The promise of retinoids to fight against cancer. Nat Rev Cancer 2001, 1(3):181-193.
76. Soprano D.R., Qin P., Soprano K.J. Retinoic acid receptors and cancers. Annu Rev Nutr 2004, 24:201-221.
77. Redmond K.A., Nguyen T.S., Ryan R.O. All-trans-retinoic acid nanodisks. Int J Pharm 2007, 339(1-2):246-250.
78. Singh A.T., Evens A.M., Anderson R.J., Beckstead J.A., Sankar N., Sassano A., et al. All trans retinoic acid nanodisks enhance retinoic acid receptor mediated apoptosis and cell cycle arrest in mantle cell lymphoma. Br J Haematol 2010, 150(2):158-169.
79. Ghosh M., Singh A.T.K., Xu W.W., Sulchek T., Gordon L.I., Ryan R.O. Curcumin nanodisks: formulation and characterization. Nanomedicine 2011, 7(2):162-167.
80. Singh A.T., Ghosh M., Forte T.M., Ryan R.O., Gordon L.I. Curcumin nanodisk-induced apoptosis in mantle cell lymphoma. Leuk Lymphoma 2011, 52(8):1537-1543.
81. Khumsupan P., Ramirez R., Khumsupan D., Narayanaswami V. Apolipoprotein E LDL receptor-binding domain-containing high-density lipoprotein: a nanovehicle to transport curcumin, an antioxidant and anti-amyloid bioflavonoid. Biochim Biophys Acta 2011, 1808(1):352-359.
82. Ikon N., Su B., Hsu F.F., Forte T.M., Ryan R.O. Exogenous cardiolipin localizes to mitochondria and prevents TAZ knockdown-induced apoptosis in myeloid progenitor cells. Biochem Biophys Res Commun 2015, 464(2):580-585.
83. Bayburt T.H., Sligar S.G. Self-assembly of single integral membrane proteins into soluble nanoscale phospholipid bilayers. Protein Sci 2003, 12(11):2476-2481.
84. Baas B.J., Denisov I.G., Sliger S.G. Homotropic cooperativity of monomeric cytochrome P450 3A4 in a nanoscale native bilayer environment. Arch Biochem Biophys 2004, 430(2):218-228.
85. Bayburt T.H., Sligar S.G. Membrane protein assembly into nanodiscs. FEBS Lett 2010, 584(9):1721-1727.
86. Tokatlian T., Segura T. siRNA applications in nanomedicine. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2010, 2(3):305-315.
87. Leng Q., Woodle M.C., Lu P.Y., Mixson A.J. Advances in systemic siRNA delivery. Drugs Future 2009, 34(9):721.
88. Davidson B.L., McCray P.B. Current prospects for RNA interference-based therapies. Nat Rev Genet 2011, 12(5):329-340.
89. Wolfrum C., Shi S., Jayaprakash K.N., Jayaraman M., Wang G., Pandey R.K., et al. Mechanisms and optimization of in vivo delivery of lipophilic siRNAs. Nat Biotechnol 2007, 25(10):1149-1157.
90. Ghosh M., Ren G., Simonsen J.B., Ryan R.O. Cationic lipid nanodisks as an siRNA delivery vehicle. Biochem Cell Biol 2014, 92(3):200-205.
91. Wadsater M., Maric S., Simonsen J.B., Mortensen K., Cardenas M. The effect of using binary mixtures of zwitterionic and charged lipids on nanodisc formation and stability. Soft Matter 2013, 9(7):2329-2337.
92. Farokhzad O.C., Langer R. Impact of nanotechnology on drug delivery. ACS Nano 2009, 3(1):16-20.
93. Wang J., Jia J.T., Liu J.P., He H.L., Zhang W.L., Li Z.H. Tumor targeting effects of a novel modified paclitaxel-loaded discoidal mimic high density lipoproteins. Drug Deliv 2013, 20(8):356-363.
94. Sabnis N., Nair M., Israel M., McConathy W.J., Lacko A.G. Enhanced solubility and functionality of valrubicin (AD-32) against cancer cells upon encapsulation into biocompatible nanoparticles. Int J Nanomedicine 2012, 7:975-983.
95. Yuan Y., Wang W., Wang B., Zhu H., Zhang B., Feng M. Delivery of hydrophilic drug doxorubicin hydrochloride-targeted liver using apoAI as carrier. J Drug Target 2013, 21(4):367-374.
96. Chandar N., Amenta J., Kandala J.C., Lombardi B. Liver cell turnover in rats fed a choline-devoid diet. Carcinogenesis 1987, 8(5):669-673.
97. Weinstein S., Emmanuel R., Jacobi A.M., Abraham A., Behlke M.A., Sprague A.G., et al. RNA inhibition highlights Cyclin D1 as a potential therapeutic target for mantle cell lymphoma. Plos One 2012, 7(8).
98. Duivenvoorden R., Tang J., Cormode D.P., Mieszawska A.J., Izquierdo-Garcia D., Ozcan C., et al. A statin-loaded reconstituted high-density lipoprotein nanoparticle inhibits atherosclerotic plaque inflammation. Nat Commun 2014, 5:3065.
99. Frias M.A., Lang U., Gerber-Wicht C., James R.W. Native and reconstituted HDL protect cardiomyocytes from doxorubicin-induced apoptosis. Cardiovasc Res 2010, 85(1):118-126.
100. Samuel V.T., Shulman G.I. Mechanisms for insulin resistance: common threads and missing links. Cell 2012, 148(5):852-871.
101. Jonas A. Reconstitution of high-density lipoproteins. Methods Enzymol 1986, 128:553-582.
102. Tall A.R., Small D.M., Deckelbaum R.J., Shipley G.G. Structure and thermodynamic properties of high density lipoprotein recombinants. J Biol Chem 1977, 252(13):4701-4711.
103. Lund-Katz S., Lyssenko N.N., Nickel M., Nguyen D., Chetty P.S., Weibel G., et al. Mechanisms responsible for the compositional heterogeneity of nascent high density lipoprotein. J Biol Chem 2013, 288(32):23150-23160.
104. Massey J.B., Pownall H.J. Cholesterol is a determinant of the structures of discoidal high density lipoproteins formed by the solubilization of phospholipid membranes by apolipoprotein A-I. Biochim Biophys Acta 2008, 1781(5):245-253.
105. Pownall H.J., Pao Q., Hickson D., Sparrow J.T., Kusserow S.K., Massey J.B. Kinetics and mechanism of association of human-plasma apolipoproteins with dimyristoylphosphatidylcholine - effect of protein-structure and lipid clusters on reaction-rates. Biochemistry 1981, 20(23):6630-6635.
106. Saito H., Dhanasekaran P., Nguyen D., Holvoet P., Lund-Katz S., Phillips M.C. Domain structure and lipid interaction in human apolipoproteins A-I and E, a general model. J Biol Chem 2003, 278(26):23227-23232.
107. Lyssenko N.N., Hata M., Dhanasekaran P., Nickel M., Nguyen D., Chetty P.S., et al. Influence of C-terminal alpha-helix hydrophobicity and aromatic amino acid content on apolipoprotein A-I functionality. Biochim Biophys Acta 2012, 1821(3):456-463.
108. Kono M., Tanaka T., Tanaka M., Vedhachalam C., Chetty P.S., Nguyen D., et al. Disruption of the C-terminal helix by single amino acid deletion is directly responsible for impaired cholesterol efflux ability of apolipoprotein A-I Nichinan. J Lipid Res 2010, 51(4):809-818.
109. Kim Y., Fay F., Cormode D.P., Sanchez-Gaytan B.L., Tang J., Hennessy E.J., et al. Single step reconstitution of multifunctional high-density lipoprotein-derived nanomaterials using microfluidics. ACS Nano 2013, 7(11):9975-9983.
110. Ritchie T.K., Grinkova Y.V., Bayburt T.H., Denisov I.G., Zolnerciks J.K., Atkins W.M., et al. Reconstitution of membrane proteins in phospholipid bilayer nanodiscs. Method Enzymol 2009, 464:211-231.
111. Larsen J., Hatzakis N.S., Stamou D. Observation of inhomogeneity in the lipid composition of individual nanoscale liposomes. J Am Chem Soc 2011, 133(28):10685-10687.
112. Skar-Gislinge N., Simonsen J.B., Mortensen K., Feidenhans'l R., Sligar S.G., Moller B.L., et al. Elliptical structure of phospholipid bilayer nanodiscs encapsulated by scaffold proteins: casting the roles of the lipids and the protein. J Am Chem Soc 2010, 132(39):13713-13722.
113. Martinez-Beamonte R., Lou-Bonafonte J.M., Martinez-Gracia M.V., Osada J. Sphingomyelin in high-density lipoproteins: structural role and biological function. Int J Mol Sci 2013, 14(4):7716-7741.
114. Sorci-Thomas M.G., Owen J.S., Fulp B., Bhat S., Zhu X., Parks J.S., et al. Nascent high density lipoproteins formed by ABCA1 resemble lipid rafts and are structurally organized by three apoA-I monomers. J Lipid Res 2012, 53(9):1890-1909.
115. Subbaiah P.V., Liu M. Role of sphingomyelin in the regulation of cholesterol esterification in the plasma-lipoproteins - inhibition of lecithin-cholesterol acyltransferase reaction. J Biol Chem 1993, 268(27):20156-20163.
116. Arimoto I., Saito H., Kawashima Y., Miyajima K., Handa T. Effects of sphingomyelin and cholesterol on lipoprotein lipase-mediated lipolysis in lipid emulsions. J Lipid Res 1998, 39(1):143-151.
117. Kucerka N., Marquardt D., Harroun T.A., Nieh M.P., Wassall S.R., de Jong D.H., et al. Cholesterol in bilayers with PUFA chains: doping with DMPC or POPC results in sterol reorientation and membrane-domain formation. Biochemistry 2010, 49(35):7485-7493.
118. McMullen T.P., Lewis R.N., McElhaney R.N. Differential scanning calorimetric study of the effect of cholesterol on the thermotropic phase behavior of a homologous series of linear saturated phosphatidylcholines. Biochemistry 1993, 32(2):516-522.
119. Yancey P.G., de la Llera-Moya M., Swarnakar S., Monzo P., Klein S.M., Connelly M.A., et al. High density lipoprotein phospholipid composition is a major determinant of the bi-directional flux and net movement of cellular free cholesterol mediated by scavenger receptor BI. J Biol Chem 2000, 275(47):36596-36604.
120. Ma C.I.J., Beckstead J.A., Thompson A., Hafiane A., Wang R.H.L., Ryan R.O., et al. Tweaking the cholesterol efflux capacity of reconstituted HDL. Biochem Cell Biol 2012, 90(5):636-645.
121. Urban S., Zieseniss S., Werder M., Hauser H., Budzinski R., Engelmann B. Scavenger receptor BI transfers major lipoprotein-associated phospholipids into the cells. J Biol Chem 2000, 275(43):33409-33415.
122. Rigotti A., Acton S.L., Krieger M. The class B scavenger receptors SR-BI and CD36 are receptors for anionic phospholipids. J Biol Chem 1995, 270(27):16221-16224.
123. Ahsan F., Rivas I.P., Khan M.A., Torres Suarez A.I. Targeting to macrophages: role of physicochemical properties of particulate carriers--liposomes and microspheres--on the phagocytosis by macrophages. J Control Release 2002, 79(1-3):29-40.
124. Massey J.B., She H.S., Gotto A.M., Pownall H.J. Lateral distribution of phospholipid and cholesterol in apolipoprotein A-I recombinants. Biochemistry 1985, 24(25):7110-7116.
125. Nakano M., Fukuda M., Kudo T., Miyazaki M., Wada Y., Matsuzaki N., et al. Static and dynamic properties of phospholipid bilayer nanodiscs. J Am Chem Soc 2009, 131(23):8308-8312.
126. Debnath A., Schafer L.V. Structure and dynamics of phospholipid nanodiscs from all-atom and coarse-grained simulations. J Phys Chem B 2015, 119(23):6991-7002.
127. Jonas A., Kezdy K.E., Williams M.I., Rye K.A. Lipid transfers between reconstituted high-density lipoprotein complexes and low-density lipoproteins - effects of plasma-protein factors. J Lipid Res 1988, 29(10):1349-1357.
128. Phillips M.C., Johnson W.J., Rothblat G.H. Mechanisms and consequences of cellular cholesterol exchange and transfer. Biochim Biophys Acta 1987, 906(2):223-276.
129. Nanjee M.N., Doran J.E., Lerch P.G., Miller N.E. Acute effects of intravenous infusion of ApoA1/phosphatidylcholine discs on plasma lipoproteins in humans. Arterioscler Thromb Vasc Biol 1999, 19(4):979-989.
130. Brinton E.A., Eisenberg S., Breslow J.L. Human HDL cholesterol levels are determined by apoA-I fractional catabolic rate, which correlates inversely with estimates of HDL particle size. Effects of gender, hepatic and lipoprotein lipases, triglyceride and insulin levels, and body fat distribution. Arterioscler Thromb 1994, 14(5):707-720.
131. Tardy C., Goffinet M., Boubekeur N., Ackermann R., Sy G., Bluteau A., et al. CER-001, a HDL-mimetic, stimulates the reverse lipid transport and atherosclerosis regression in high cholesterol diet-fed LDL-receptor deficient mice. Atherosclerosis 2014, 232(1):110-118.
132. Murphy A.J., Funt S., Gorman D., Tall A.R., Wang N. Pegylation of high-density lipoprotein decreases plasma clearance and enhances antiatherogenic activity. Circ Res 2013, 113(1):e1-e9.
133. Gabizon A., Shmeeda H., Barenholz Y. Pharmacokinetics of pegylated liposomal doxorubicin - review of animal and human studies. Clin Pharmacokinet 2003, 42(5):419-436.
134. Gabizon A., Catane R., Uziely B., Kaufman B., Safra T., Cohen R., et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res 1994, 54(4):987-992.
135. Diditchenko S., Gille A., Pragst I., Stadler D., Waelchli M., Hamilton R., et al. Novel formulation of a reconstituted high-density lipoprotein (CSL112) dramatically enhances ABCA1-dependent cholesterol efflux. Arterioscler Thromb Vasc Biol 2013, 33(9):2202-2211.
136. Sorci-Thomas M.G., Bhat S., Thomas M.J. Activation of lecithin:cholesterol acyltransferase by HDL ApoA-I central helices. Clin Lipidol 2009, 4(1):113-124.